Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
4.12.2024 13:00:00 EET | Business Wire | Press release
We are excited to share our latest development status.
We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved.
In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. We had presented these results at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation.
DFP-17729 is a novel approach to neutralize the acidic cancer microenvironment, and several patents on related inventions have been granted in major countries around the world, and its potential of efficacy has been published in peer-reviewed journals.
We will first identify DFP-17729 as a treatment for refractory pancreatic cancer, for which effective treatment is not yet available, and then seek to expand the indication to other types of cancer through partnership with major global pharmaceutical companies.
Please take notice of our own innovative approach for miserable cancer patients and contact us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204497142/en/
Contacts
Inquires
Yasundo Yamasaki, Ph.D.
Director, Business Development
Delta-Fly Pharma Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.delta-flyp
harma.co.jp%2Fen%2F&esheet=54161588&newsitemid=20241204497142&lan=en-US&anchor=h
ttps%3A%2F%2Fwww.delta-flypharma.co.jp%2Fen%2F&index=1&md5=adcd527d539f6849e5052
6d1e02039b2
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 16:00:00 EET | Press release
ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer at ViTAA Medical said: “The SVS deserves credit for its foresight in embracing advances in AI, digital healt
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 15:39:00 EET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 15:30:00 EET | Press release
Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specification that lets any payment provider add Klarna to AI agent checkout. “Agentic
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 12:05:00 EET | Press release
SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing on a rolling basis through December 2026. It takes SatSure’s total capital raised to INR 427 crore (c. USD 46 millio
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 11:16:00 EET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom